![A Real IMV with the CRA Academy Interns and meeting with their PI and Clinical Research Coordinator - YouTube A Real IMV with the CRA Academy Interns and meeting with their PI and Clinical Research Coordinator - YouTube](https://i.ytimg.com/vi/dpHLKQqyH8w/maxresdefault.jpg)
A Real IMV with the CRA Academy Interns and meeting with their PI and Clinical Research Coordinator - YouTube
![IMV Inc. on Twitter: "#ICYMI $IMV held a Research & Development webinar describing the science behind the DPX® technology, past pre-clinical and clinical results as well as initiated clinical trials. Watch the IMV Inc. on Twitter: "#ICYMI $IMV held a Research & Development webinar describing the science behind the DPX® technology, past pre-clinical and clinical results as well as initiated clinical trials. Watch the](https://pbs.twimg.com/media/FNACaURX0AIA2XP.jpg)
IMV Inc. on Twitter: "#ICYMI $IMV held a Research & Development webinar describing the science behind the DPX® technology, past pre-clinical and clinical results as well as initiated clinical trials. Watch the
![Q&A: Why IMV's DPX-Survivac shows promise in treating ovarian cancer - Drug Discovery and Development Q&A: Why IMV's DPX-Survivac shows promise in treating ovarian cancer - Drug Discovery and Development](https://www.drugdiscoverytrends.com/wp-content/uploads/2021/02/Screen-Shot-2021-02-17-at-11.57.56-AM-1024x676.png)
Q&A: Why IMV's DPX-Survivac shows promise in treating ovarian cancer - Drug Discovery and Development
![An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients | Scientific Reports An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-88509-9/MediaObjects/41598_2021_88509_Fig1_HTML.png)
An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients | Scientific Reports
![IMV Inc. on Twitter: "Our CEO Andrew Hall shared insights on IMV's anticipated 2022 company milestones in a recent @pharmasalmanac roundtable. Learn more about IMV's technology and clinical trials here: https://t.co/IteqiAsvtc https://t.co/hUGk6obvbR" / IMV Inc. on Twitter: "Our CEO Andrew Hall shared insights on IMV's anticipated 2022 company milestones in a recent @pharmasalmanac roundtable. Learn more about IMV's technology and clinical trials here: https://t.co/IteqiAsvtc https://t.co/hUGk6obvbR" /](https://pbs.twimg.com/media/FPLusv7VEAksF39.jpg)
IMV Inc. on Twitter: "Our CEO Andrew Hall shared insights on IMV's anticipated 2022 company milestones in a recent @pharmasalmanac roundtable. Learn more about IMV's technology and clinical trials here: https://t.co/IteqiAsvtc https://t.co/hUGk6obvbR" /
![IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer | Business Wire IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer | Business Wire](https://mms.businesswire.com/media/20210810005569/en/897811/23/IMV_Logos_IMV-Logo_Primary.jpg)